Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors (NCT05732831)
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Who can join: Review the eligibility criteria below.
Location: Stanford University — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Stanford University — Palo Alto, California
- Grand Valley Oncology — Grand Junction, Colorado
- Florida Cancer Specialists & Research Institute — Lake Mary, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
- University Chicago Medicine — Chicago, Illinois
- Carle Cancer Center — Urbana, Illinois
- Midwestern Regional Medical Center, City of Hope Chicago — Zion, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Cancer Center — Detroit, Michigan
- New York University Langone Health — New York, New York
- Sarah Cannon Tennessee Oncology — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- Next Oncology Virginia — Fairfax, Virginia
- CHU de Brest — Brest,
- Centre Berard Leon — Lyon,
- Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS — Saint-Herblain,
- Institute Gustav Roussy — Villejuif,
- Vall d'Hebron Barcelona Hospital — Barcelona, Catalonia
- Hospital HM Nou Delfos — Barcelona,
- ICO l'Hospitalet - Hospital Duran i Reynals — Barcelona,
- Hospital Universitario Fundacion Jimenez Diaz — Madrid,
- Hospital de Sanchinarro — Madrid,
- Hospital Universitario Virgen de la Victoria — Málaga,
📞 Contact the Study Coordinator
Phone: (857) 320-4899
Email: clinicaltrials@tangotx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Locally Advanced Solid Tumor
- A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors — Portland, Oregon
- ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) — San Diego, California
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Orange, California
- A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours — New Haven, Connecticut
- A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) — Irvine, California
Explore by condition: All Locally Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.